Amimestrocel in China for Steroid-Refractory Acute GVHD: Evidence, Approved Use, Cost and International Access
- MedBridgeNZ
- Jul 26
- 8 min read
Key Takeaways
Amimestrocel (trade name: 睿铂生; transliterated as Ruibosheng) has received conditional approval from the Chinese National Medical Products Administration (NMPA) for a highly specific hematological indication.
It is restricted to patients aged 14 and older with steroid-refractory acute graft-versus-host disease (SR-aGVHD) predominantly involving the gastrointestinal tract.
The publicly reported medicine price in China is 158,400 RMB for an initial eight-infusion course. This amount represents the medicine price only and does not include hospital, administrative, or travel costs.
International patient access requires preliminary hospital review of the clinical records, confirmation that the institution can accept the patient, and completion of the relevant visa and travel procedures.
Quick Answer
China has conditionally approved Amimestrocel Injection (艾米迈托赛注射液; trade name 睿铂生), a human umbilical cord-derived mesenchymal stem cell product, for patients aged 14 years and older with steroid-refractory acute graft-versus-host disease predominantly involving the gastrointestinal tract.
The pivotal evidence comes from a 54-patient multicenter, single-arm study in which amimestrocel was added to protocol-mandated anti-CD25 antibody therapy. The reported Day 28 overall response rate was 63.0%, but the absence of a concurrent control group means that outcomes cannot be attributed to amimestrocel alone.
International access is not automatic. A receiving hematology or transplant team must review the patient’s records, assess medical suitability, confirm hospital acceptance, and determine whether the treatment is clinically appropriate. An S2 visa may be relevant for short-term medical treatment, subject to consular determination.
Verified Entity Information
Item | Verified Information |
Official English Name | Amimestrocel Injection |
Chinese Name | 艾米迈托赛注射液 |
Trade Name | 睿铂生 ( transliterated as Ruibosheng) |
Regulator | China National Medical Products Administration (NMPA) |
Approval Status | Conditionally approved |
Approved Population | Patients aged 14 years and older |
Approved Indication | Steroid-refractory acute GVHD with predominant gastrointestinal involvement |
Cell Source | Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) |
Evidence Design | 54-patient multicenter, single-arm pivotal study |
Clinical Decision-Maker | Receiving hematology/transplant team |
What this approval does not cover
Amimestrocel is not NMPA-approved for the commercial treatment of anti-aging, arthritis, spinal cord injury, diabetes, or autism. Ongoing clinical research in other conditions does not constitute an approved commercial indication.
Where Does Amimestrocel Fit Within the Broader Treatment Landscape?
Acute graft-versus-host disease (aGVHD) is a severe complication following allogeneic hematopoietic stem cell transplantation, where donor immune cells attack the recipient's tissues. When first-line systemic corticosteroid treatments fail, the condition is classified as steroid-refractory (SR-aGVHD).
Amimestrocel is one China-approved option for a narrowly defined patient population. It is not presented here as a replacement for all established second-line treatments, and treatment selection must be made exclusively by the patient’s treating hematology or transplant team. Treatment choices depend heavily on disease grading, specific organ involvement, active infections, blood counts, prior therapies, and the protocols of the receiving transplant center.
Understanding the Amimestrocel (hUC-MSCs) Intervention
Definition: Amimestrocel is a living cell pharmaceutical consisting of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs). Its manufacturing process uses three-dimensional biodegradable microcarrier suspension technology designed to support scalable, controlled production and batch-to-batch consistency.
Function: Amimestrocel is understood to exert immunomodulatory effects through cell-to-cell interactions and paracrine signaling. Proposed mechanisms include the modulation of activated immune cells and the secretion of factors involved in inflammatory regulation and tissue repair.
Clinical Context: Amimestrocel is approved in China for eligible patients aged 14 years and older with steroid-refractory acute GVHD predominantly involving the gastrointestinal tract. In the pivotal study, it was administered in addition to protocol-defined anti-CD25 monoclonal antibody therapy. The treatment regimen for an individual patient is determined solely by the treating hematology or transplant team.
Evidence Snapshot
Study Design: Multicenter, single-arm pivotal study involving 54 patients with gastrointestinal-involved steroid-refractory acute GVHD.
Reported Finding: Day 28 overall response rate (ORR) was 63.0% (95% CI, 48.7%–75.7%), including a complete response rate of 55.6% (95% CI, 41.4%–69.1%). Estimated overall survival at Day 360 was 65.8% (95% CI, 51.1%–77.0%).
Clinical Limitations & Safety: Because the study had no concurrent control group and included mandatory background anti-CD25 therapy, the reported outcomes cannot be attributed to amimestrocel alone. Treatment-emergent adverse events were reported in 53 of 54 patients. The investigators reported no treatment-related serious adverse events or infusion-related toxicity. However, the small, single-arm study was not designed to exclude uncommon or long-term risks.
Drug Pricing and Potential Additional Costs
When evaluating cross-border healthcare pathways, understanding the distinction between drug-acquisition costs and total medical expenses is paramount.
The publicly reported medicine price is 19,800 RMB per infusion. Eight infusions would therefore amount to 158,400 RMB (approximately $22,000 USD). This amount represents the publicly reported medicine price only and does not include hospital or related costs.
Important Financial Consideration: Patients must also budget for:
Additional infusions, if prescribed: In the pivotal study, patients with a partial response at Day 28 could receive four additional weeks of treatment, resulting in up to 16 infusions.
Hospital admission, outpatient, or International Medical Services (IMS) fees.
Specialist consultations and multidisciplinary reviews.
Routine blood work, imaging, infection control, and supportive care.
Potential intensive care (ICU) or complication management.
Medical translation, accommodation, transportation, and exchange rate fluctuations.
Institutional Access and Care Coordination
International patients can access amimestrocel only through a Chinese medical institution with appropriate hematology or transplant expertise, prescribing authority, confirmed formulary access, and the capacity to accept the individual patient.
The first publicly reported commercial prescription was issued at Peking University People’s Hospital in June 2025. Subsequent reporting indicates that the medicine has reached multiple transplant centers in China. However, current availability, international-patient acceptance, supply, and admission requirements must be reconfirmed directly with each institution.
Furthermore, live cellular pharmaceuticals require strict cold-chain distribution. Public reporting indicates that amimestrocel uses the AliHealth “Mashang Fangxin” platform for product-level supply-chain traceability. The information available through the traceability interface may include product and distribution records; the exact data visible to the patient or hospital should be confirmed at the point of care.
MedBridgeNZ can help organize, translate, and prepare your records for submission to a Chinese hematology or transplant service. Learn more about our medical record translation, hospital submission, and cross-border coordination services.
Representative Administrative Pathway
The following pathway is illustrative of the administrative steps required for cross-border care. It does not describe a specific MedBridgeNZ patient, nor does it guarantee clinical acceptance.
Clinical Context: A patient’s treating hematology team identifies GI-predominant SR-aGVHD and wishes to explore international therapeutic options.
Records Prepared for Review: The patient’s comprehensive transplant summary, HLA information, pathology reports, and immunosuppressive logs are compiled, formatted, and translated.
Institutional Routing: MedBridgeNZ coordinates the submission of these formatted records to the International Medical Services (IMS) department of a relevant Chinese hematology center.
Clinical Review: The receiving Chinese physicians independently review the case to determine whether the patient may be accepted and whether amimestrocel could be clinically considered. Fitness for international travel must be assessed separately by the patient’s current treating team and, where relevant, the airline or medical transport provider.
Administrative Next Steps: If the hospital issues a formal admission or proposed treatment notice, the patient may apply for an S2 short-term private-affairs visa (subject to consular approval) and coordinate travel logistics.
Please note: Individual medical outcomes vary significantly depending on baseline health, prior treatments, and specific disease progression. Do not travel before receiving explicit hospital acceptance.
Frequently Asked Questions
1. Can a clinically unstable patient travel to China for treatment?
Patients requiring active ICU support or unable to tolerate routine commercial air travel would ordinarily require specialist-led medical transport assessment. MedBridgeNZ cannot determine fitness to fly or arrange travel without appropriate clinical clearance.
2. What exact records are needed for an institutional readiness check?
A comprehensive review typically requires: the transplant summary and date; donor and HLA information; GVHD onset, grade, and affected organs; corticosteroid dose, duration, and response; previous second-line treatments; recent endoscopy or GI pathology; current medications; latest blood counts, liver, and kidney function; infection records; and current oxygen or mobility status.
3. How is international commercial insurance coordinated for Chinese tertiary hospitals?
Some international medical departments may support direct billing with selected insurers. Coverage is hospital-, insurer-, policy-, and treatment-specific, and written pre-authorization should always be obtained before travel.
4. How long does an S2 visa application typically take?
An S2 short-term private-affairs visa may be relevant for medical treatment involving a stay of no more than 180 days. Some Chinese visa offices quote approximately four working days for regular processing after a complete application and passport have been formally accepted. This does not necessarily include preliminary online review, appointment waiting time, requests for additional documents, passport delivery, or individual verification. Processing times and expedited services vary by country and consular jurisdiction.
For a step-by-step overview of document preparation and the distinction between S1 and S2 private-affairs visas, see our S1/S2 visa application guide. The applicable category, supporting documents, and final decision remain subject to the responsible Chinese embassy, consulate, or visa center.
5. Is amimestrocel approved for off-label use such as anti-aging or arthritis for international patients?
No. Anti-aging, arthritis, spinal cord injury, and autism are not included in amimestrocel’s NMPA-approved commercial indication. Such services should not be represented as NMPA-approved uses of amimestrocel.
6. Are there specific payment methods required for international patients covering therapy costs?
Foreign credit cards are not universally accepted at all hospital billing windows. Patients often utilize mobile payment methods (such as Alipay or WeChat Pay linked to international cards), direct wire transfers, or direct billing channels through high-end medical insurance networks, depending on the specific hospital's policies.
Request a Hospital Submission Readiness Check
MedBridgeNZ can help organize, translate, and prepare your records for submission to a Chinese hematology or transplant service. The receiving hospital—not MedBridgeNZ—determines medical eligibility, acceptance, treatment protocols, and travel suitability.
Actionable Logistics Pathway
Document Translation and Formatting: Clients submit relevant medical records and imaging reports. We provide professional medical translation and organize the dossier according to the submission requirements communicated by the selected hospital.
Institutional Submission and Review Coordination: We identify potentially relevant departments using publicly available institutional information and coordinate record submission for administrative intake and physician-led clinical review. MedBridgeNZ does not determine clinical eligibility or recommend a treatment.
Logistics and On-the-Ground Support: If hospital acceptance is granted and travel is deemed safe, our team facilitates on-the-ground logistics, including navigating real-name registration systems, bilingual hospital accompaniment, and local accommodation coordination.
Patients seeking support with cross-border medical coordination, medical-record translation, hospital submission, or remote hospital review coordination may contact MedBridgeNZ to discuss the available administrative pathways. Submit your initial inquiry via our Contact Us page.
References
Amimestrocel Injection Approved with Conditions for Marketing by China NMPA. National Medical Products Administration.https://english.nmpa.gov.cn/2025-06/11/c_1101502.htm
Mesenchymal Stromal Cells as Add-On Therapy to Anti-CD25 Antibodies for Treating Gastrointestinal-Involved Steroid-Refractory Acute Graft-Versus-Host Disease: A Multicenter, Single-Arm, Pivotal Clinical Trial. Stem Cell Research & Therapy.https://link.springer.com/article/10.1186/s13287-026-04982-x
Acute Graft-Versus-Host Disease. Nature Reviews Disease Primers.https://www.nature.com/articles/s41572-023-00438-1
China’s First Stem Cell Medicine Enters Commercial Use with AliHealth Support. Xinhua News Agency.https://www.news.cn/tech/20250616/49f9d15b2f8c4521970e2f051f2a1419/c.html
China’s First Commercial Prescription for Amimestrocel Issued at Peking University People’s Hospital. Beijing Economic-Technological Development Area.https://kfqgw.beijing.gov.cn/ywdt/kjcgzhgd/kjqy/202506/t20250620_4246443.html
Amimestrocel Reported to Have Reached More Than 70 Transplant Centers in China. Xinhua News Agency.https://www.news.cn/tech/20260603/6ee5678a34c641328350d293ae6fc7ad/c.html
Regulations of the People’s Republic of China on Administration of the Entry and Exit of Foreigners. Ministry of Foreign Affairs of the People’s Republic of China.https://cs.mfa.gov.cn/wgrlh/lhqz/lhqzjjs/201401/t20140121_961576.shtml
Disclaimer: MedBridgeNZ acts strictly as an international medical concierge and logistics coordinator. We do not provide medical treatment, diagnosis, clinical screening, or treatment recommendations. This content has been evidence-checked for informational purposes and does not constitute medical guidance. Always consult your treating hematology or transplant team before pursuing cross-border care. Last evidence review: July 2026.
